3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
3
Tumor-Agnostic
2
NET
2
Endocrine
2
Thoracic
1
Lymphoid
1
Conditions
Multiple Myeloma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myeloid, Acute
5
Lymphoma, Non-Hodgkin
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Primary Myelofibrosis
3
Lymphoma
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Leukemia, Myeloid, Accelerated Phase
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Prolymphocytic
2
Leukemia, Mast-Cell
2
Leukemia, Large Granular Lymphocytic
2
Leukemia, Hairy Cell
2
Leukemia, Biphenotypic, Acute
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Interventions
pembrolizumab
3
temsirolimus
1
spartalizumab
1
poly ICLC
1
patritumab
1
durvalumab
1
atezolizumab
1
advexin
1
Tetanus Toxoid
1
Sunitinib
1
Rifampin
1
Radiation
1
Nivolumab
1
Midazolam
1
Ketoconazole
1
Ipilimumab
1
Interleukin-15
1
Brentuximab Vedotin
1
Blood Specimen Collection
1
Axitinib
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Sunitinib
×
Lymphoid
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts